References
Chatterjee K, Zhang J, Honbo N, & Karliner JS (2010). Doxorubicin cardiomyopathy. Cardiology 115: 155-162.
D’Elia E, Iacovoni A, Vaduganathan M, Lorini FL, Perlini S, & Senni M (2017). Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides. European journal of heart failure 19: 710-717.
Elshabrawy HA, Essani AE, Szekanecz Z, Fox DA, & Shahrara S (2017). TLRs, future potential therapeutic targets for RA. Autoimmun Rev 16: 103-113.
Henrick BM, Yao XD, Taha AY, German JB, & Rosenthal KL (2016). Insights into Soluble Toll-Like Receptor 2 as a Downregulator of Virally Induced Inflammation. Front Immunol 7: 291.
Hu C, Zhang X, Zhang N, Wei WY, Li LL, Ma ZG, et al. (2020). Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clinical and translational medicine.
Hubers SA, & Brown NJ (2016). Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 133: 1115-1124.
Jacquet A, & Robinson C (2020). Proteolytic, lipidergic and polysaccharide molecular recognition shape innate responses to house dust mite allergens. Allergy 75: 33-53.
Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, et al. (2017). LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. American journal of translational research 9: 5473-5484.
Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, et al. (2010). TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 106: 796-808.
Li B, Xia Y, & Hu B (2020). Infection and atherosclerosis: TLR-dependent pathways. Cellular and molecular life sciences : CMLS 77: 2751-2769.
Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, et al. (2018). Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation 138: 696-711.
Li X, Zhu Q, Wang Q, Zhang Q, Zheng Y, Wang L, et al. (2020). Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice. Cardiovascular drugs and therapy.
Liang S, Xinyong C, Hongmin Z, Jing W, Lang H, & Ping Z (2018). TLR2 and TLR3 expression as a biomarker for the risk of doxorubicin-induced heart failure. Toxicology letters 295: 205-211.
Lilley E, Stanford SC, Kendall DE, Alexander SPH, Cirino G, Docherty JR, et al. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British journal of pharmacology 177: 3611-3616.
Lillyblad MP (2015). Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. The Annals of pharmacotherapy 49: 1237-1251.
Mann DL, Greene SJ, Givertz MM, Vader JM, Starling RC, Ambrosy AP, et al. (2020). Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. (2014). Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England journal of medicine 371:993-1004.
Nozaki N, Shishido T, Takeishi Y, & Kubota I (2004). Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 110: 2869-2874.
Oatmen KE, Zile MR, Burnett JC, Jr., & Spinale FG (2018). Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review. JAMA cardiology 3: 1232-1243.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. (2020). The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. The Journal of physiology.
Pop-Moldovan AL, Trofenciuc NM, Darabantiu DA, Precup C, Branea H, Christodorescu R, et al. (2017). Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin-induced cardiotoxicity. Cancer gene therapy 24:203-207.
Riad A, Bien S, Gratz M, Escher F, Westermann D, Heimesaat MM, et al. (2008). Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. European journal of heart failure 10: 233-243.
Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, et al. (2016). LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. European journal of heart failure 18: 386-393.
Tacar O, Sriamornsak P, & Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. The Journal of pharmacy and pharmacology 65: 157-170.
Turner AJ, Isaac RE, & Coates D (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. BioEssays : news and reviews in molecular, cellular and developmental biology 23:261-269.
Vejpongsa P, & Yeh ET (2014). Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Journal of the American College of Cardiology 64: 938-945.
von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, et al. (2015). Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circulation Heart failure 8: 71-78.
Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K, et al. (2017). LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. Journal of molecular and cellular cardiology 108: 138-148.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, et al. (2016). 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology 68: 1476-1488.
Yang HL, Hsieh PL, Hung CH, Cheng HC, Chou WC, Chu PM, et al.(2020). Early Moderate Intensity Aerobic Exercise Intervention Prevents Doxorubicin-Caused Cardiac Dysfunction Through Inhibition of Cardiac Fibrosis and Inflammation. Cancers 12.
Table Biometric and echocardiographic parameters of the experimental mice.